AGEN (Agenus) Cyclically Adjusted Revenue per Share: $12.22 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

AGEN Agenus Inc AGEN
43 GF Score
Price $7.16
GF Value $3.78
Valuation Significantly Overvalued
! 12 Warning Signs
View Full Analysis

What is Agenus Cyclically Adjusted Revenue per Share?

Agenus AGEN -2.32% 43 Cyclically Adjusted Revenue per Share is $12.22 as of Jun. 2026. GuruFocus rates AGEN with a GF Score™ of 43/100 and a GF Value™ of $3.78 (Significantly Overvalued). The stock has 12 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Agenus's adjusted revenue per share for the three months ended in Jun. 2026 was $0.835. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $12.22 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Agenus's average Cyclically Adjusted Revenue Growth Rate was -0.70% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 3.90% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 6.30% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 8.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Agenus was 21.70% per year. The lowest was -11.20% per year. And the median was 4.10% per year.

As of today (2026-08-18), Agenus's current stock price is $7.155. Agenus's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was $12.22. Agenus's Cyclically Adjusted PS Ratio of today is 0.59.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Agenus was 21.13. The lowest was 0.13. And the median was 6.18.


Agenus  (NAS:AGEN) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Agenus's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=7.155/12.22
=0.59

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Agenus was 21.13. The lowest was 0.13. And the median was 6.18.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Agenus Cyclically Adjusted Revenue per Share Related Terms


Agenus Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Agenus's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Agenus Cyclically Adjusted Revenue per Share Chart

Agenus Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.18 10.78 11.71 12.23 12.09

Agenus Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.30 12.26 12.09 12.21 12.22

AGEN vs FULC, IRD, TTRX: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, Agenus's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Agenus Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Agenus's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Agenus's Cyclically Adjusted PS Ratio falls into.


AGEN
43GF Score
Agenus Inc AGEN
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Agenus Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Agenus's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.835/333.9520*333.9520
=0.835

Current CPI (Jun. 2026) = 333.9520.

Agenus Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 1.020 241.428 1.411
201612 1.276 241.432 1.765
201703 5.766 243.801 7.898
201706 0.848 244.955 1.156
201709 0.672 246.819 0.909
201712 1.655 246.524 2.242
201803 0.319 249.554 0.427
201806 3.024 251.989 4.008
201809 2.227 252.439 2.946
201812 1.073 251.233 1.426
201903 10.752 254.202 14.125
201906 2.334 256.143 3.043
201909 2.898 256.759 3.769
201912 5.004 256.974 6.503
202003 2.086 258.115 2.699
202006 3.186 257.797 4.127
202009 1.624 260.280 2.084
202012 3.240 260.474 4.154
202103 1.170 264.877 1.475
202106 0.963 271.696 1.184
202109 20.505 274.310 24.963
202112 1.579 278.802 1.891
202203 2.008 287.504 2.332
202206 1.511 296.311 1.703
202209 1.588 296.808 1.787
202212 1.865 296.797 2.098
202303 1.444 301.836 1.598
202306 1.440 305.109 1.576
202309 1.286 307.789 1.395
202312 4.364 306.746 4.751
202403 1.375 312.332 1.470
202406 1.116 314.175 1.186
202409 1.165 315.301 1.234
202412 1.172 315.605 1.240
202503 0.984 319.799 1.028
202506 0.914 322.561 0.946
202509 0.920 324.800 0.946
202512 0.995 324.054 1.025
202603 0.881 330.213 0.891
202606 0.835 333.952 0.835

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of $12.22 mean?
Agenus (AGEN) has a Cyclically Adjusted Revenue per Share of $12.22 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Agenus and its competitors.
Is Agenus' Cyclically Adjusted Revenue per Share too high?
Agenus' current Cyclically Adjusted Revenue per Share is $12.22. Overall, Agenus has a GF Score™ of 43/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Agenus' Cyclically Adjusted Revenue per Share compare to FULC and IRD?
Agenus' Cyclically Adjusted Revenue per Share of $12.22 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Agenus and its competitors. Agenus's current Cyclically Adjusted Revenue per Share is $12.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Agenus stock overvalued right now?
Based on GuruFocus' analysis, Agenus (AGEN) is currently considered Significantly Overvalued. The stock's GF Value™ is $3.78, compared to a current price of $7.16 — trading 89.3% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is $12.22. Agenus' overall GF Score™ is 43/100 with 12 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Agenus (AGEN), the current Cyclically Adjusted Revenue per Share is $12.22 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Agenus (AGEN) Overvalued in 2026?

Based on GuruFocus' analysis, Agenus stock appears to be overvalued. The current stock price of $7.16 is trading 89.3% above its estimated GF Value™ of $3.78. GuruFocus considers Agenus to be Significantly Overvalued.

Key valuation signals for AGEN:

  • Cyclically Adjusted Revenue per Share: $12.22
  • GF Value™: $3.78 vs. price of $7.16 (89.3% above fair value)
  • GF Score™: 43/100 with 12 warning signs

No single metric tells the full story. See the AGEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Agenus Business Description

Other Exchanges AJ8:Germany
Address 3 Forbes Road, Lexington, MA, USA, 02421
Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.
43GF Score

Get the complete analysis for AGEN

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.16
Price
$3.78
GF Value